Note 6 – Intangible Assets

Intangible assets, at September 30, 2019 and 2018, consist of the following:


	Useful	Gross		Accumulated
September 30, 2019	Life (years)	Amount		Amortization		Net
Acquired Customer Base	5 to 15	$	682,000	$	632,000	$	50,000
Know How	15		512,000		384,000		128,000
Trade Name	Indefinite		257,000		—		257,000
Patents	20		223,000		31,000		192,000
Biomedical Technologies	5		260,000		260,000		—
		$	1,934,000	$	1,307,000	$	627,000


	Useful	Gross		Accumulated
September 30, 2018	Life (years)	Amount		Amortization		Net
Acquired Customer Base	5 to 15	$	719,000	$	601,000	$	118,000
Know How	15		512,000		350,000		162,000
Trade Name	Indefinite		272,000		—		272,000
Patents	20		223,000		20,000		203,000
Biomedical Technologies	5		260,000		260,000		—
		$	1,986,000	$	1,231,000	$	755,000

Amortization expense for the years ended September 30, 2019 and 2018 was $108,000 and $112,000, respectively. In fiscal year 2018, the Company recorded an impairment loss of $182,000.

Estimated amortization expense for each of the next five fiscal years is as follows:


	2020		2021		2022		2023		2024		Thereafter		Total
Acquired Customer Base	$	50,000	$	—	$	—	$	—	$	—	$	—	$	50,000
Know How		34,000		34,000		34,000		26,000		—		—		128,000
Patents		11,000		11,000		11,000		11,000		11,000		137,000		192,000
	$	95,000	$	45,000	$	45,000	$	37,000	$	11,000	$	137,000	$	370,000